D-BAS™ sits at the convergence of three of the fastest-growing sectors in healthcare: AI diagnostics, wearable biosensors, and personalised Digital Twin medicine. The market timing is exceptional. The technology is ready.
D-BAS™ operates at the intersection of three independently massive markets, each reinforcing the others. No single competitor occupies this combined space with a vertically integrated solution.
Custom multi-sensor array and signal fusion pipeline protected by an active patent strategy. The hardware moat ensures that even if AI models are replicated, the data quality advantage persists.
D-BAS™ Pod generates high-margin B2B hardware + SaaS revenue from hospitals and diagnostic chains. Home System creates a mass-market recurring subscription stream — two independent growth engines.
Every user generates irreplaceable longitudinal biosignal data that compounds in predictive value over time. This creates a self-reinforcing proprietary dataset — the most defensible moat in digital health.
Designed from inception for EU MDR and FDA 510(k) pathways. Initial markets (UAE, EU) have clear regulatory frameworks and active government support for digital health innovation.
Unlike competitors who use off-the-shelf sensors or third-party AI, D-BAS™ controls the full stack — from custom hardware to Digital Twin. This yields data quality and latency advantages impossible to replicate with modular approaches.
All existing wearables compare against population averages. D-BAS™ compares each individual against their own baseline — eliminating false positives and detecting anomalies up to 3× earlier.
Every additional session makes each user's Digital Twin more accurate. Every additional user makes the platform's AI models more powerful. Both effects are self-reinforcing and accelerate over time.
Core signal fusion and AI biomarker extraction methods are subject to active patent filings, creating legal protections in key markets including UAE, EU, and US.
5-Layer architecture designed, validated, and documented. Core patent applications filed. EvatLabs LLC entity established in UAE.
D-BAS™ Pod prototype development. First clinical validation study with UAE hospital partner. Home System beta hardware design.
CE mark and UAE MoHAP regulatory submission for D-BAS™ Pod. Home System beta to 200 users. Series A fundraising.
D-BAS™ Pod commercial launch in UAE and EU. Home System public launch. Expansion to KSA and GCC markets.
US FDA clearance. Platform licensing to hospital networks and insurance providers. 1M+ Digital Twin profiles.
We are currently raising our Seed round to fund D-BAS™ Pod prototyping and our first clinical validation study. Contact us for the full investor deck and financial model.